GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Real Brands Inc (OTCPK:RLBD) » Definitions » Debt-to-EBITDA

Real Brands (Real Brands) Debt-to-EBITDA : -2.11 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Real Brands Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Real Brands's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.98 Mil. Real Brands's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.08 Mil. Real Brands's annualized EBITDA for the quarter that ended in Dec. 2023 was $-0.50 Mil. Real Brands's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -2.11.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Real Brands's Debt-to-EBITDA or its related term are showing as below:

RLBD' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -7.68   Med: -0.19   Max: 29.02
Current: -0.89

During the past 10 years, the highest Debt-to-EBITDA Ratio of Real Brands was 29.02. The lowest was -7.68. And the median was -0.19.

RLBD's Debt-to-EBITDA is ranked worse than
100% of 657 companies
in the Drug Manufacturers industry
Industry Median: 1.69 vs RLBD: -0.89

Real Brands Debt-to-EBITDA Historical Data

The historical data trend for Real Brands's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Real Brands Debt-to-EBITDA Chart

Real Brands Annual Data
Trend Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.68 -0.11 -0.19 -0.91 -0.89

Real Brands Quarterly Data
Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.69 -0.27 -1.49 -1.23 -2.11

Competitive Comparison of Real Brands's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Real Brands's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Real Brands's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Real Brands's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Real Brands's Debt-to-EBITDA falls into.



Real Brands Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Real Brands's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.978 + 0.079) / -1.195
=-0.88

Real Brands's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.978 + 0.079) / -0.5
=-2.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Real Brands  (OTCPK:RLBD) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Real Brands Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Real Brands's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Real Brands (Real Brands) Business Description

Traded in Other Exchanges
N/A
Address
12 Humbert Street, North Providence, RI, USA, 02991
Real Brands Inc is a brand-building company in the legal hemp and cannabis industry. Its brand includes CBD Pharmacy, Omega Hemp, Hempaid, and Humboldt among others. The company sells its hemp-based products to the wholesale and retail markets.
Executives
James Wells Dobbins director 5201 INTERCHANGE WAY, LOUISVILLE KY 40229
Thomas Kidrin officer: President and CEO 11 ROYAL ROAD, BROOKLINE MA 02445
Christopher John Ryan officer: CFO 11 ROYAL RD, BROOKLINE MA 02445
Leonard Toboroff director 39 N MOORE ST, STE 6B, NEW YORK NY 10013
Peter N Christos director
Turning Point Brands, Inc. 10 percent owner 5201 INTERCHANGE WAY, LOUISVILLE KY 40229
Brett S. Spitalny officer: Chief Operating Officer 2 SOUTH UNIVERSITY DRIVE, SUITE 220, PLANTATION FL 33324
Jerry Pearring director, officer: President & CEO 2 SOUTH UNIVERSITY DRIVE, SUITE 220, PLANTATION FL 33324
Ross E Silvey director 7633 EAST 63RD PLACE, #220, TULSA OK 74133
Terry J Turner director 7633 EAST 63RD PLACE, #220, TULSA OK 74133
Bernie Gurr officer: Chief Financial Officer 32751 MATTHEW DRIVE, DANA POINT CA 92629
Bruce Macgregor officer: Chief Executive Officer, Pres. 5092 RHOADS AVENUE UNIT A, SANTA BARBARA CA 93111
Ken Wiedrich director 43180 BUSINESS PARK DRIVE SUITE 202, TEMECULA CA 92590

Real Brands (Real Brands) Headlines

From GuruFocus

RLBD's Kidrin on Revs, M&A, and TPB

By ACCESSWIRE ACCESSWIRE 03-14-2022

Real Brands Inc. Uplists to OTCQB

By GuruFocusNews GuruFocusNews 03-02-2022